Editorial & Opinion
Reply to Letter to the Editor regarding "Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer".
| العنوان: | Reply to Letter to the Editor regarding "Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer". |
|---|---|
| المؤلفون: | Maniakas A; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hu MI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gunn GB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zafereo M; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| المصدر: | Head & neck [Head Neck] 2024 Jul; Vol. 46 (7), pp. 1848-1849. Date of Electronic Publication: 2024 Apr 22. |
| نوع المنشور: | Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley And Sons Country of Publication: United States NLM ID: 8902541 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0347 (Electronic) Linking ISSN: 10433074 NLM ISO Abbreviation: Head Neck Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : John Wiley And Sons Original Publication: New York, NY : J. Wiley, c1989- |
| مواضيع طبية MeSH: | Thyroid Neoplasms*/radiotherapy , Thyroid Neoplasms*/surgery , Thyroid Neoplasms*/pathology, Humans ; Carcinoma, Neuroendocrine/surgery ; Carcinoma, Neuroendocrine/radiotherapy ; Carcinoma, Neuroendocrine/pathology ; Thyroidectomy ; Radiotherapy, Adjuvant |
| References: | Maniakas A, Sullivan A, Hu MI, et al. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024;46:328‐335. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double‐blind phase III trial. J Clin Oncol. 2012;30:134‐141. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639‐3646. Subbiah V, Wolf J, Konda B, et al. Tumour‐agnostic efficacy and safety of selpercatinib in patients with RET fusion‐positive solid tumours other than lung or thyroid tumours (LIBRETTO‐001): a phase 1/2, open‐label, basket trial. Lancet Oncol. 2022;23:1261‐1273. Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161:137‐146. Parikh R, Hess LM, Esterberg E, Bhandari NR, Kaye JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer. Thyroid Res. 2022;15:2. Website. Accessed April 3, 2024. https://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf. Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer—local disease control in the modern era. Head Neck. 2008;30:883‐888. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567‐610. |
| SCR Disease Name: | Thyroid cancer, medullary |
| تواريخ الأحداث: | Date Created: 20240422 Date Completed: 20240605 Latest Revision: 20240605 |
| رمز التحديث: | 20240605 |
| DOI: | 10.1002/hed.27780 |
| PMID: | 38646970 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0347 |
|---|---|
| DOI: | 10.1002/hed.27780 |